Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
40.97
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jun 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,323
Open
40.97
Bid (Size)
40.98 (1)
Ask (Size)
41.31 (1)
Prev. Close
40.97
Today's Range
40.97 - 40.97
52wk Range
39.91 - 66.38
Shares Outstanding
2,222,113,553
Dividend Yield
5.57%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Bristol Myers Squibb Announces Dividend
Today 6:59 EDT
From
Bristol Myers Squibb
Via
Business Wire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Performance
YTD
-22.35%
-22.35%
1 Month
-5.51%
-5.51%
3 Month
-20.59%
-20.59%
6 Month
-20.20%
-20.20%
1 Year
-37.95%
-37.95%
More News
Read More
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
Via
FinancialNewsMedia
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
June 10, 2024
Via
Benzinga
Smart Money Is Betting Big In BMY Options
June 07, 2024
Via
Benzinga
6% Yield Bristol Myers Squibb Value Trap Or Long-Term Opportunity?
May 31, 2024
Via
Talk Markets
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
June 15, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
3 High-Yield Dividend Stocks for Income Now and Growth Later
June 14, 2024
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
June 13, 2024
From
Bristol Myers Squibb
Via
Business Wire
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
June 11, 2024
Via
InvestorPlace
7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too)
June 10, 2024
Via
InvestorPlace
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
June 08, 2024
Via
Talk Markets
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
June 08, 2024
Via
InvestorPlace
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
June 07, 2024
Via
Benzinga
Exposures
Product Safety
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
June 06, 2024
Via
Benzinga
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients
June 04, 2024
Via
Benzinga
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Bristol Myers Squibb
Via
Business Wire
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday
June 03, 2024
Via
Benzinga
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
June 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
June 03, 2024
Via
The Motley Fool
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
June 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
May 31, 2024
Via
Benzinga
Exposures
Product Safety
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.